My mind immediately jumped to pharma outfit Forest Laboratories (FRX), but it has been acquired by Actavis (ACT). But that’s OK. ACT stock has been on quite a tear itself, having tripled over the past two years. It has been on an acquisition binge, and Forest was just its latest addition.
Forest’s EPS, balance sheet and cash flow were outstanding, so ACT definitely got itself a catch there. Actavis’ financials are fantastic, with adjusted Ebitda having increased almost 60% in FY13, and more than doubling year-over-year in Q4.
Combined, these two powerhouses have more upside. ACT stock has 45 branded pharmaceuticals and hundreds of generics. Forest has numerous pharmaceuticals, of which Lexapro is probably the most well known.
ACT is up more than 30% YTD. It will go higher.